Human parathyroid hormone for the treatment of osteoporosis in post-menopausal women

2013 ◽  
Author(s):  
Vesna Kusec ◽  
Jonathan Adachi ◽  
Peter Tugwell ◽  
George A Wells ◽  
Ana Marusic ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Human Parathyroid Hormone ◽  
Treatment Of Osteoporosis ◽  
Menopausal Women ◽  
Post Menopausal

Human parathyroid hormone for the treatment of osteoporosis in post-menopausal women.

2001 ◽  
Author(s):  
Lisa M. Waldegger ◽  
Ann Cranney ◽  
Jonathan Adachi ◽  
Peter Tugwell ◽  
George A Wells
Keyword(s):  
Parathyroid Hormone ◽  
Human Parathyroid Hormone ◽  
Treatment Of Osteoporosis ◽  
Menopausal Women ◽  
Post Menopausal

Raloxifene for the prevention and treatment of osteoporosis in post-menopausal women

2000 ◽  
Author(s):  
A Cranney ◽  
V Robinson ◽  
G Guyatt ◽  
N Krolicki ◽  
JD Adachi ◽  
...  
Keyword(s):  
Treatment Of Osteoporosis ◽  
Menopausal Women ◽  
Prevention And Treatment ◽  
Post Menopausal

scholarly journals Malignant Myeloma in a Patient after Treatment for Osteoporosis with Teriparatide; a Rare Coincidence

2008 ◽  
Vol 1 ◽  
pp. CCRep.S1026 ◽  
Author(s):  
Terje Forslund ◽  
Anna-Mari Koski ◽  
Arvo Koistinen ◽  
Anu Sikiö
Keyword(s):  
Parathyroid Hormone ◽  
Theoretical Basis ◽  
Bone Structure ◽  
Exclusion Criterion ◽  
Human Parathyroid Hormone ◽  
Treatment Of Osteoporosis ◽  
Teriparatide Treatment ◽  
Direct Association ◽  
Metastasis Development ◽  
Structure Regulation

A breakthrough in understanding of mechanisms of bone structure regulation has brought about the introduction of the new synthetic recombinant human parathyroid hormone 1–34 (PTH1-34; Teriparatide) in the treatment of osteoporosis. These mechanisms, involving the RANKL, RANK, and osteoprotegerin system, are also known to be involved in malignant myeloma (MM) and tumor and bone metastasis development. We report a case in which MM was found after treatment of osteoporosis with teriparatide. We were unable to demonstrate any direct association between the MM and teriparatide treatment. However, it seemed intriguing that similar mechanisms are activated in the development of MM as those being working during teriparatide treatment. In the view of our case, we propose that MM by examination of serum protein fraction should be searched for prior to treatment with teriparatide as it is an exclusion criterion in teriparatide treatment of secondary osteoporosis. A search for other metastatic diseases prior to teriparatide treatment should eventually also be considered. The theoretical basis for our proposal is discussed.

A novel human parathyroid hormone (1-34) analog for the treatment of osteoporosis

Peptides ◽  
2009 ◽  
Vol 30 (6) ◽  
pp. 1173-1180 ◽  
Author(s):  
Jiao Feng ◽  
Yanhua Liu ◽  
Yun Xing ◽  
Huaqian Wang ◽  
Taiming Li ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Human Parathyroid Hormone ◽  
Treatment Of Osteoporosis

Preliminary Trial of Low Doses of Human Parathyroid Hormone 1–34 Peptide in Treatment of Osteoporosis

1976 ◽  
Vol 50 (2) ◽  
pp. 14P-14P
Author(s):  
J. Reeve ◽  
J. A. Parsons ◽  
G. W. Tregear ◽  
A. J. Darby ◽  
R. Hesp ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Low Doses ◽  
Human Parathyroid Hormone ◽  
Treatment Of Osteoporosis ◽  
Preliminary Trial

scholarly journals Teriparatide (Biosynthetic Human Parathyroid Hormone 1-34): A New Paradigm in the Treatment of Osteoporosis

2004 ◽  
Vol 94 (6) ◽  
pp. 260-270 ◽  
Author(s):  
Kim T. Brixen ◽  
Brixen Christensen ◽  
Charlotte Ejersted ◽  
Bente Lomholt Langdahl
Keyword(s):  
Parathyroid Hormone ◽  
Human Parathyroid Hormone ◽  
New Paradigm ◽  
Treatment Of Osteoporosis

scholarly journals Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life

Reumatismo ◽  
2020 ◽  
Vol 72 (2) ◽  
pp. 71-74
Author(s):  
G. Adami ◽  
A. Giollo ◽  
M. Rossini ◽  
G. Orsolini ◽  
C. Benini ◽  
...  
Keyword(s):  
Fracture Risk ◽  
Real Life ◽  
Therapeutic Agents ◽  
Risk Profile ◽  
Routine Clinical Practice ◽  
Baseline Risk ◽  
Major Osteoporotic Fracture ◽  
Treatment Of Osteoporosis ◽  
Menopausal Women ◽  
Post Menopausal

In this retrospective study, we intended to investigate the baseline fracture risk profile in patients who started treatment with different anti-osteoporotic medications. We analyzed retrospectively the fracture risk calculated with DeFRA, a validated FRAX derived tool, in women who started an anti-osteoporotic treatment from 2010 to 2017. We analyzed baseline data of 12,024 post-menopausal women aged over 50 years. Teriparatide initiators had a baseline 10-year risk of major osteoporotic fracture of 82.1% with a Standard Deviation (SD) of 66.5%. Denosumab initiators and zoledronic acid initiators had a greater 10-year baseline risk of fracture (54.3%, SD 46.5% and 47.0%, SD 42.0 respectively) than patients initiated on alendronate (24.9%, SD 34.6%) and patients initiated on risedronate (23.9%, SD 24.1%). Using DeFRA, a FRAX™ derived tool, we showed significantly different fracture risk profiles in women who were started on various therapeutic agents for the treatment of osteoporosis in routine clinical practice.

Sign in / Sign up

Export Citation Format

Share Document